Charles Schwab Investment Management Inc. Decreases Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Charles Schwab Investment Management Inc. lowered its stake in Gossamer Bio, Inc. (NASDAQ:GOSS) by 2.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,228,077 shares of the company’s stock after selling 33,520 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.54% of Gossamer Bio worth $1,211,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GOSS. NEA Management Company LLC lifted its holdings in Gossamer Bio by 14.2% during the second quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after purchasing an additional 2,255,025 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Gossamer Bio by 31.3% during the 2nd quarter. Acadian Asset Management LLC now owns 3,592,765 shares of the company’s stock worth $3,235,000 after purchasing an additional 856,380 shares during the last quarter. Marshall Wace LLP lifted its stake in Gossamer Bio by 170.8% in the 2nd quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock valued at $3,002,000 after buying an additional 2,103,766 shares in the last quarter. Monaco Asset Management SAM boosted its holdings in Gossamer Bio by 390.3% in the 2nd quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock worth $2,456,000 after buying an additional 2,170,104 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Gossamer Bio by 204.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock worth $1,844,000 after buying an additional 1,375,000 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Stock Performance

NASDAQ:GOSS opened at $0.87 on Wednesday. Gossamer Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.60. The company has a market cap of $197.71 million, a P/E ratio of -2.73 and a beta of 1.85. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The company’s 50-day moving average price is $0.84 and its 200-day moving average price is $0.87.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $9.48 million during the quarter, compared to analysts’ expectations of $4.52 million. On average, sell-side analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Monday, November 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Gossamer Bio has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.